Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …

This article proposes codes for the primary tumor categories of adenocarcinoma in situ (AIS)
and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in …

Introduction Nodal status is considered to be one of the most reliable indicators of the
prognosis in patients with lung cancer and thus is indispensable in determining the optimal …

The IASLC Staging and Prognostic Factors Committee has collected a new database of
94,708 cases donated from 35 sources in 16 countries around the globe. This has now been …

Cel. Cisplatyna z gemcytabiną jest standardowym leczeniem I linii chorych na zaawansowanego
niedrobnokomórkowego raka płuca (NSCLC). Badania kliniczne II fazy wykazały …

Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …

… of interest statement: José Baselga has been in receipt of a research grant from AstraZeneca
and honoraria to attend advisory boards and to give talks on ZD1839; Johan Vansteenkiste …

Background An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage III, …

Background Outcomes are poor for patients with previously treated, advanced or metastatic
non-small-cell lung cancer (NSCLC). The anti-programmed death ligand 1 (PD-L1) antibody …

Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …